Literature DB >> 7534915

Serum levels of integrins in chronic liver diseases.

M Yamauchi1, Y Mizuhara, Y Maezawa, G Toda.   

Abstract

The serum levels of beta 1 integrin (microgram/ml) were significantly higher in the patients with chronic persistent hepatitis (2.59 +/- 0.04), chronic active hepatitis (3.45 +/- 0.13), cirrhosis (4.77 +/- 0.30) and hepatocellular carcinoma (4.71 +/- 0.49) than in normal subjects (2.11 +/- 0.08). Serum levels of beta 3 integrin (microgram/ml) were significantly higher in the patients with chronic active hepatitis (10.48 +/- 1.22), liver cirrhosis (13.55 +/- 1.54) and hepatocellular carcinoma (14.1 +/- 1.77) when compared with normal subjects (5.51 +/- 0.52). A positive correlation was found between serum levels of beta 1 and beta 3 integrins (p < 0.001). A strong positive correlation was observed between serum levels of beta 1 integrin and histologic features, particularly in the degree of hepatic fibrosis, while no correlation was found between serum levels of beta 3 integrin and hepatic fibrosis. Immunohistochemical studies revealed that the beta 1 integrin was present on the plasma membranes of hepatocytes and sinusoidal lining cells in the normal liver, and was increased in fibrotic areas, and on the plasma membranes of hepatocytes and sinusoidal lining cells of the chronic liver disease. However, no positive staining for beta 3 integrin was observed in fibrotic area. The serum level of beta 1 integrin in patients with chronic liver diseases may therefore be a useful marker of hepatic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7534915     DOI: 10.1016/S0344-0338(11)81005-8

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  2 in total

1.  Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.

Authors:  Tao Liu; Wei-Jun Qian; Marina A Gritsenko; David G Camp; Matthew E Monroe; Ronald J Moore; Richard D Smith
Journal:  J Proteome Res       Date:  2005 Nov-Dec       Impact factor: 4.466

2.  Functional annotation and enrichment analysis of differentially expressed serum proteins in patients with type 2 diabetes after dapagliflozin.

Authors:  Yan-Xue Zhao; Sarul Borjigin; Zhao-Li Yan
Journal:  World J Diabetes       Date:  2022-03-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.